There's been a lot of talk in pharma circles about making sure that their drug development programmes and clinical trials are patient-centric – but what can be done for pe
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh